Trial Profile

A phase 3 validation study of zuranolone in Japan

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zuranolone (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

10 Oct 2024 Status changed to completed, according to a Shionogi media release.
27 Sep 2024 According to a Shionogi media release, primary endpoint (change from baseline in the HAM-D total score) has been met.
27 Sep 2024 According to a Shionogi media release, company announced that Shionogi submitted today a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). The NDA submission is based on data from the Phase 3 program conducted by Shionogi in Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com